Related Experiment Video
Updated: Aug 6, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Antithrombotics and Gastrointestinal Prophylaxis: A Systematic Review.
Ian Lancaster1, Vikas Sethi, Deep Patel
1From the HCA Healthcare/USF Morsani College of Medicine GME Programs, Largo Medical Center, Largo, FL.
Gastrointestinal bleeding is a risk with antithrombotic drugs. This review examines evidence for gastrointestinal prophylaxis (proton pump inhibitors or histamine 2 receptor antagonists) in patients using antiplatelet or anticoagulant therapy.
Area of Science:
- Cardiology
- Gastroenterology
- Pharmacology
Background:
- Antithrombotic medications, including antiplatelet agents and anticoagulants, are crucial for managing cardiovascular conditions.
- Gastrointestinal bleeding is a significant adverse event associated with antithrombotic therapy.
- Gastrointestinal prophylaxis is frequently considered for patients on these medications.
Purpose of the Study:
- To systematically review current evidence and recommendations for gastrointestinal prophylaxis in patients receiving antithrombotic medications.
- To address the scarcity of guidelines on concurrent use of gastrointestinal protective agents with antithrombotic regimens.
Main Methods:
- Systematic review of existing literature.
- Analysis of evidence regarding gastrointestinal prophylaxis strategies.
- Evaluation of recommendations for patients on single or combination antithrombotic therapy.
Main Results:
- Evidence and specific recommendations for gastrointestinal prophylaxis in patients on antithrombotic therapy are limited.
- Proton pump inhibitors and histamine 2 receptor antagonists are common methods for gastrointestinal prophylaxis.
- The review synthesizes available data to inform clinical practice.
Conclusions:
- Further research and clearer guidelines are needed for optimal gastrointestinal prophylaxis in patients on antithrombotic medications.
- Clinicians should carefully consider the risks and benefits of gastrointestinal prophylaxis for individual patients.
- This review provides a foundation for understanding current practices and identifying knowledge gaps.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

